Metrics as of 10/16/2026, 12:39 AM (Berlin time), refresh in progress.
Arbutus Biopharma Stock
Arbutus Biopharma Corp
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Lindsay Androski
- Employees
- 19
- Market cap
- $850 M
- IPO
- 26/07/2007
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a…
Arbutus Biopharma stock: price history
1D
+2.4%
1W
+2.6%
1M
-15.2%
6M
-8.3%
YTD
-10.8%
1Y
-4.0%
2Y
+4.4%
5Y
+5.1%
10Y
+49.5%
Next earnings date
Next earnings date
16/11/2026 (in 30 days)
Volatility around earnings
~32% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Arbutus Biopharma
Analyst assessment of Arbutus Biopharma
PRICE TARGET LOW
US$8.50
CONSENSUS
US$8.50
MEDIAN
US$8.50
PRICE TARGET HIGH
US$8.50
0
STRONG BUY
8
BUY
2
HOLD
0
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 14/11/2025
Arbutus Biopharma stock metrics
P/E
5.43
P/B
3.27
EV/EBITDA
5.45
RETURN ON EQUITY
-2.0%
NET MARGIN
-507.2%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
76.0%
FLOAT SHARES
150,534,504
AVG. DAILY VOLUME (30D)
6,753,056
Insider transactions (SEC)
Androski Lindsay
Sawhney Roger
Nguyen Tuan
Beardsley Robert A
Roivant Sciences Ltd.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Arbutus Biopharma stock
What does Arbutus Biopharma do?
Arbutus Biopharma Corp is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Lindsay Androski, the company employs around 19 people.
The IPO was on 26/07/2007; the stock trades on NASDAQ under the ticker ABUS.
What do analysts say about Arbutus Biopharma stock?
10 analysts rate the stock, the consensus is Buy (as of 14/11/2025).
The average price target is US$8.50, ranging from US$8.50 to US$8.50, with a median of US$8.50.
This is an external assessment, not a statement by Market Jury.
When does Arbutus Biopharma report next?
The next earnings date is 16/11/2026.
Around past earnings, price swings were roughly -32% stronger than usual.
Does Arbutus Biopharma pay a dividend?
No, Arbutus Biopharma currently does not pay a dividend.
Which stocks are comparable to Arbutus Biopharma?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Arbutus Biopharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess Arbutus Biopharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.